What are the commercial brand names for tirzepatide (for type 2 diabetes and obesity)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tirzepatide Brand Names

Tirzepatide is marketed under two brand names by Eli Lilly: Mounjaro® for type 2 diabetes mellitus and Zepbound® for chronic weight management in adults with obesity. 1, 2, 3, 4

Brand-Specific Indications

Mounjaro®

  • FDA approved in May 2022 for type 2 diabetes mellitus 1, 4, 5
  • Available as once-weekly subcutaneous injection at doses of 5,10, and 15 mg 6
  • Demonstrated A1C reduction of 1.9% to 2% with >87% of patients reaching A1C target of <7% 6

Zepbound®

  • FDA approved in November 2023 for chronic weight management 1, 3
  • Same dosing regimen as Mounjaro (5,10,15 mg weekly) 2
  • Indicated for adults with obesity or overweight with at least one weight-related comorbidity 1
  • Additionally approved in December 2024 as the first prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity 6

Clinical Context

Both formulations contain the same active ingredient—tirzepatide, a dual GIP/GLP-1 receptor agonist—but are marketed under different brand names based on their primary indication 6. The distinction is primarily regulatory and insurance-related rather than pharmacological.

Key efficacy data:

  • Weight reduction of 22.5% at 72 weeks with 15 mg dose in obesity trials 6
  • In patients with type 2 diabetes and obesity, weight reduction of 12.8-14.7% with 10-15 mg doses 6
  • Formulated as once-weekly subcutaneous injection with half-life of 116.7 hours 6

The medication is titrated monthly from a starting dose of 2.5 mg weekly to a maximum of 15 mg weekly 6.

Related Questions

What is the recommended dosing regimen for tirzepatide (Mounjaro) in adults with type 2 diabetes, including starting dose, titration schedule, and target dose?
What is the recommended dosing schedule, contraindications, and monitoring for Mounjaro (tirzepatide) in adult patients with type 2 diabetes?
Are Zepbound (tirzepatide) and Mounjaro (tirzepatide) chemically identical in composition?
Can I start Mounjaro (tirzepatide) while taking mirtazapine 7.5 mg twice daily, sertraline 150 mg each morning, and clonazepam 0.25 mg at night?
How should I inform a 49-year-old male patient with type 2 diabetes mellitus well controlled on tirzepatide (Mounjaro) 7.5 mg weekly, hyperlipidemia managed with rosuvastatin and fenofibrate, and intermittent erectile dysfunction treated with tadalafil 10 mg, about medication refills, increasing tadalafil to 20 mg, upcoming labs (hemoglobin A1c, renal function, urine microalbumin/creatinine ratio, complete blood count), his mildly decreasing platelet count, and follow‑up plans via the patient portal?
A patient is taking trazodone 200 mg at night and continues to have insomnia; what management steps should be taken?
What causes lesions at the petrous apex?
What laboratory tests should be obtained before initiating mifepristone (Korlym) or relacorilant (Recorlev)?
How should increased anger or irritability be managed in a patient taking Wellbutrin (bupropion)?
Do tolterodine and donepezil have opposing mechanisms of action?
What are the clinical implications and recommended workup for splenomegaly identified on a CT scan?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.